Transcatheter aortic valve implantation (TAVI) is a relatively new technique offering a treatment option to patients for whom an open-heart surgery represents a high risk of fatality. Due to the percutaneous delivery method of this treatment, there are challenges associated. In this technique the native aortic valve is not resected, making it difficult to judge the required size of the implant and making the sealing unpredictable. After implantation, 50% of the patients suffer from at least a mild degree of leakage alongside the implant, also known as paravalvular regurgitation [1].

This content is only available via PDF.
You do not currently have access to this content.